CytoDyn Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

Stock Information for CytoDyn Inc

Loading

Please wait while we load your information from QuoteMedia.